Document:

EXHIBIT 10.7

 Exhibit 10.7 
  
 AWARD AGREEMENT 
  
 [Date] 
  
 The Executive Compensation Committee of the Gannett Board of Directors has approved an award to you under the 2001 Omnibus Incentive Compensation Plan as
amended by the Rules for employees of the Subsidiaries of Gannett U.K. Limited (hereinafter referred to collectively as the “U.K. Sub-Plan”), as set forth below. 
  
 This Award Agreement and the enclosed Terms and Conditions effective as of [date], constitute the formal agreement governing
this award. 
  
 Please sign both copies of this Award Agreement to
evidence your agreement with the terms hereof. Keep one copy and return the other to Gannett’s Compensation Department, attention Sonia E. Kelly. 
  
 Please keep the enclosed Terms and Conditions for future reference. Until further notice, they will apply to any future grants you receive. 
  

							
	 Granted To:
	 	 	 	 Employee Location:
	 	 
				
	 Options Granted:
	 	 	 	 	 	 
				
	 Grant Date:
	 	 [date]
	 	 Option Expiration Date:
	 	 [10th Anniversary]

  
 Option Price Per
Share:    $ 
  

					
	 Vesting Schedule:
	 	 [1st Anniversary]
	 	 25%

			
	 	 	 [2nd Anniversary]
	 	 50%

			
	 	 	 [3rd Anniversary]
	 	 75%

			
	 	 	 [4th Anniversary]
	 	 100%

  

					
	 	 	 Gannett Co., Inc.

			
	  

	 	 By:
	 	  

	 Employee Signature
	 	 	 	 Roxanne V. Horning

	 	 	 	 	 Vice President/Compensation

	 	 	 	 	 and Benefits

 STOCK OPTION 
  
 TERMS AND CONDITIONS 
  
 Under the 
  
 Gannett Co., Inc. (“the Company”) 
  
 2001
Omnibus Incentive Compensation Plan 
  
 Rules for employees of the
subsidiaries of Gannett U.K. Limited 
  
 These Terms and
Conditions, dated [date], govern the grant of stock options (“Options”) under the 2001 Omnibus Incentive Compensation Plan (the “Plan”) as amended by the Rules for employees of the Subsidiaries of Gannett U.K. Limited
(hereinafter referred to collectively as the ‘U.K. Sub-Plan’), as set forth below. Terms used herein that are defined in the U.K. Sub-Plan shall have the meaning ascribed to them in the U.K. Sub-Plan. If there is any inconsistency between
the defined terms of these Terms and Conditions and the terms of the U.K. Sub-Plan, the U.K Sub-Plan’s terms shall supersede and replace the conflicting terms herein. 
  
 1. Grant of Options. Pursuant to the provisions of (i) the U.K. Sub-Plan, (ii) the individual Award Agreements
governing each grant, and (iii) these Terms and Conditions, the Company has granted to the Option Holder the number of options (“Options”) to purchase the number of shares of common stock of the Company (“Common Stock”) set forth
on the applicable Award Agreement, at the purchase price per share stated in such Award Agreement (“Option price”). 
  
 2. Exercisability. Except as otherwise provided in Section 14 below, the Options shall become exercisable as specified in the relevant Award
Agreement. The Options may be partially exercised from time to time within such percentage limitations, but no partial exercise of the Options will be permitted for less than ten shares of Common Stock. In no event shall the Options be exercisable
in whole or in part after the Option Expiration Date specified in the relevant Award Agreement. Upon an Option Holder’s termination of employment with the Company following the Option Holder’s (a) death, (b) injury or disability (as
determined under the Company’s Long Term Disability Plan), or (c) retirement at or after age 65 or early retirement at or after age 55 in accordance with the Company’s policies those Options awarded to the Option Holder will continue to
vest and may be exercised as described in Sections 6 and 7 below. Upon any other termination of employment, the Options will be automatically cancelled. 
  

 -2- 

 3. Method of Exercising Options. The Options may be exercised from time to time by written or
electronic notice (in the form prescribed by the Company) delivered to and received by the Company (unless the Option Holder elects to make a “cashless exercise”), which notice shall be signed by the Option Holder and shall state the
election to exercise the Options and the number of whole shares of Common Stock with respect to which the Options are being exercised. Such notice must be accompanied by a check payable to the Company, or such other consideration as may be provided
under the U.K. Sub-Plan, in payment of the full Option price for the number of shares purchased. As soon as practicable after it receives such notice and payment, the Company will deliver to the Option Holder a certificate or certificates for the
shares of Common Stock so purchased. The Option Holder may exercise pursuant to a “cashless exercise” procedure, subject to securities law restrictions. 
  
 4. Reduction in Number Of Shares Subject to Options. Upon the exercise of one or more rights related to Options which
have been awarded to the Option Holder on the Grant Date (as specified in the relevant Award Agreement), pursuant to the U.K. Sub-Plan, the number of shares of Common Stock subject to the Options shall be reduced one-for-one. 
  
 5. Cancellation of Options. 
  
 (a) Expiration of Term. On the Expiration Date, the unexercised
Options shall be canceled automatically to the extent not yet exercised. 
  
 (b) Termination of Employment. Except as provided in Sections 6, 7, and 14 below, or except as otherwise determined by the Executive Compensation Committee of the Board of Directors (the “Committee”)
in its sole discretion, the Options shall automatically be cancelled upon termination of the Option Holder’s employment with the Company or any of its subsidiaries for any reason. 
  
 6. Death of Option Holder. Upon the death of the Option Holder, the Options vested at the time of such death may be
exercised by the Option Holder’s personal representative, provided that such exercise occurs both before the Option Expiration Date and within one year after the Option Holder’s death. Any Options not vested as of the Option Holder’s
death will continue vesting during a period of 12 months after the option holder’s death, and to the extent vested may be exercised by the holder’s personal representatives during that period. Upon the expiration of such twelve month
period, all unexercised vested Options and all unvested Options will be cancelled. 
  

 -3- 

 7. Retirement, Disability or Redundancy. Upon termination of the Option Holder’s employment
(i) by reason of permanent disability, as determined under the Company’s Long Term Disability Plan, or (ii) on retirement at or after age 65 or early retirement at or after age 55 in accordance with the Company’s policies, the Options
vested at the time of such termination may be exercised by the Option Holder, provided that such exercise occurs both before the Option Expiration Date and within three years after the Option Holder’s termination. Any Options not vested as of
the date of termination will continue vesting during this post-termination period in accordance with the Options’ original vesting schedule. Upon the expiration of such post-termination exercise period, all unexercised vested Options and all
unvested Options will be cancelled. Upon termination of an Option Holder’s employment by reason of redundancy, any Options held at the time of such termination shall lapse immediately. 
  
 8. Non-Assignability. The Options shall not be assignable or
transferable by the Option Holder. During the life of the Option Holder, the Options shall be exercisable only by the Option Holder or by the Option Holder’s guardian or legal representative. 
  
 9. Rights as a Shareholder. The Option Holder shall have no rights as
a shareholder by reason of the Options unless and until certificates for shares of Common Stock are issued to him or her. 
  
 10. Right to Terminate Employment. Nothing in the U.K. Sub-Plan, the relevant Award Agreement or in these Terms and Conditions shall confer on the
Option Holder the right to continue in the employment of the Company or any of its subsidiaries or affect any right which the Company or any of its subsidiaries may have to terminate the employment of the Option Holder. 
  
 11. Effect of U.K. Sub-Plan. The U.K. Sub-Plan is hereby incorporated
by reference into these Terms and Conditions, and these Terms and Conditions are subject in all respects to the provisions of the U.K. Sub-Plan, including without limitation the authority of the Committee to adjust awards and to make interpretations
and other determinations with respect to all matters relating to these Terms and Conditions, the applicable Award Agreements, the U.K. Sub-Plan, and awards made pursuant thereto. These Terms and Conditions shall apply to grants of Options made to
the Option Holder from the date hereof until such time as revised Terms and Conditions are effective. 
  

 -4- 

 12. Notice. Notices hereunder shall be in writing and if to the Company shall be addressed to the
Secretary of the Company: 7950 Jones Branch Drive, McLean, Virginia 22107 and if to the Option Holder shall be addressed to the Option Holder at his or her address as it appears on the Company’s records. 
  
 13. Successors and Assigns. The applicable Award Agreement and these
Terms and Conditions shall be binding upon and inure to the benefit of the successors and assigns of the Company and, to the extent provided in Sections 6 and 8 hereof, to the heirs, legatees and personal representatives of the Option Holder.

  
 14. Change in Control Provisions. Notwithstanding
anything to the contrary in these Terms and Conditions, the following provisions shall apply to all Options granted under the attached Award Agreement: 
  
 As used in Article 15 of the Plan and in these Terms and Conditions, a “Change in Control” means the first to occur of the following:

  
 (a) the acquisition by any individual, entity or group
(within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (i) the then-outstanding shares of
common stock of the Company (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding
Company Voting Securities”); provided, however, that, for purposes of this Section, the following acquisitions shall not constitute a Change in Control: (A) any acquisition directly from the Company, (B) any acquisition by the Company, (C) any
acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or one of its affiliates or (D) any acquisition pursuant to a transaction that complies with Sections 14(c)(i), 14(c)(ii) and 14(c)(iii); 

 
 (b) individuals who, as of the date hereof, constitute the Board (the
“Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election or nomination for election by the
Company’s stockholders was approved by a vote of at least a 
  

 -5- 

 majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member
of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or
threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; 
  
 (c) consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any of
its subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any of its subsidiaries (each, a “Business Combination”), in
each case, unless, following such Business Combination, (i) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding Company Common Stock and the Outstanding Company Voting Securities immediately
prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the
election of directors, as the case may be, of the corporation or entity resulting from such Business Combination (including, without limitation, a corporation or entity that, as a result of such transaction, owns the Company or all or substantially
all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Company Common Stock and the Outstanding
Company Voting Securities, as the case may be, (ii) no Person (excluding any employee benefit plan (or related trust) of the Company or any corporation or entity resulting from such Business Combination) beneficially owns, directly or indirectly,
20% or more of, respectively, the then-outstanding shares of common stock of the corporation or entity resulting from such Business Combination or the combined voting power of the then-outstanding voting securities of such corporation or entity,
except to the extent that such ownership existed prior to the Business Combination, and (iii) at least a majority of the members of the board of directors of the corporation or entity resulting from such Business Combination were members of the
Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such Business Combination; or 
  

 -6- 

 (d) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

  
 No Option Holder who participates in any group conducting a
management buyout of the Company under the terms of which the Company ceases to be a public company may claim that such buyout is a Change in Control under this Plan and no such Option Holder shall be entitled to any payments or other benefits under
this Plan as a result of such buyout. 
  
 Acceleration
Provisions. In the event of the occurrence of a Change in Control, all outstanding Options shall become fully exercisable during their remaining term. 
  
 Legal Fees. The Company shall pay all legal fees, court costs, fees of experts and other costs and expenses when incurred by the Option Holder in
connection with any actual, threatened or contemplated litigation or legal, administrative or other proceedings involving the provisions of this Section 14, whether or not initiated by the Option Holder. 
  
 Employment Agreements. The provisions of this Section 14 shall not be
applied to or interpreted in a manner which would decrease the rights held by, or the payments owing to, an Option Holder under an employment agreement with the Company that contains specific provisions applying to U.K. Sub-Plan awards in the case
of any change in control or similar event, and if there is any conflict between the terms of such employment agreement and the terms of this Section 14, the employment agreement shall control. 
  
 15. Grant Subject to Applicable Regulatory Approvals. Any grant of
Options under the U.K. Sub-Plan is specifically conditioned on, and subject to, any regulatory approvals required in the Employee’s country. These approvals cannot be assured. If necessary approvals for grant or exercise are not obtained, the
Options may be cancelled or rescinded, or they may expire, as determined by the Company in its sole and absolute discretion. 
  
 16. Applicable Laws and Consent to Jurisdiction. The validity, construction, interpretation and enforceability of this Agreement shall be
determined and governed by the laws of the State of Delaware without giving effect to the principles of conflicts of law. For the purpose of litigating any dispute that arises under this Agreement, the parties hereby consent to exclusive
jurisdiction in Virginia and agree that such litigation shall be conducted in the courts of Fairfax County, Virginia or the federal courts of the United States for the Eastern District of Virginia. 
  

 -7-Settlement Agreement

 Exhibit 10.1 
  
 EXECUTION COPY 
  
 SETTLEMENT AGREEMENT 
  
 This Settlement Agreement, made this 31st day of October, 2004 (the “Effective Date”), is between Constar International Inc. (“Constar”) and Continental PET Technologies, Inc. (“Continental”). 
  
 WHEREAS in April, 1999, Constar’s predecessor filed a lawsuit against
Continental in the United States District Court for the District of Delaware, which action is now captioned Constar International Inc. v. Continental PET Technologies, Inc., C.A. No. 99 CV 234 (“the Action”), alleging infringement
of U.S. Patent No. 5,021,515, entitled “Packaging” (“the ‘515 Patent”); 
  
 WHEREAS Continental denies that it has made, used, sold, or offered to sell any products that infringe any claim of the ‘515 Patent; 
  
 WHEREAS Continental filed a counterclaim seeking a declaratory judgment that
the ‘515 Patent is invalid, unenforceable, and/or not infringed; 
  
 WHEREAS Constar denies that the ‘515 Patent is invalid or unenforceable; 
  
 WHEREAS in May 2000, Chevron Phillips Chemical Company and Chevron Research and Technology Company (collectively “Chevron”) intervened in the Action, claiming that the patent rights asserted by Constar
against Continental rightfully belonged to Chevron pursuant to a 1993 License Agreement, asserting an infringement claim against Continental and a cross-claim against Constar, to which Constar counterclaimed; WHEREAS Chevron subsequently settled its
infringement claim against Continental and granted a sub-license under the 1993 License Agreement to Continental (“the Chevron/Continental sub-license”), which sub-license Constar contends is invalid; 

 WHEREAS the issues relating to the respective rights of Constar and Chevron under the 1993 License
Agreement were tried to the Court in July, 2001; 
  
 WHEREAS on
November 25, 2002, the Court issued a Memorandum Opinion holding that the rights to the accused Continental products remained with Constar and had not been licensed to Chevron, and judgment was entered accordingly on March 31, 2002; 
  
 WHEREAS Continental continued to assert the validity of the
Chevron/Continental sub-license; 
  
 WHEREAS on June 30, 2003,
Constar supplemented its counterclaim against Chevron to assert that Chevron induced Continental’s continued infringement by granting the Continental sub-license; 
  
 WHEREAS Constar and Chevron have settled the claims between them, have entered into a new license agreement, and have
entered into a Settlement Agreement executed concurrently herewith; 
  
 WHEREAS Continental and Chevron have amended their settlement and terminated the Chevron/Continental sub-license; 
  
 WHEREAS the parties hereto desire to settle and resolve the Action; 
  
 NOW THEREFORE, in full and complete settlement of the disputes between them, in consideration of the mutual covenants and
agreements contained herein, and intending to be legally bound, the parties hereto agree as follows: 
  
 1. Upon the execution of this Agreement: 
  

 - 2 - 

 (a) Owens-Illinois, Inc. shall pay to Constar the sum of twenty-five million one hundred
thousand U.S. dollars ($25,100,000) by wire transfer of immediately available funds to the below referenced account: 
  
 Constar International Inc. 
 SunTrust Bank 
 ABA: 061000104 
 Account: 1000007625964 
 SWIFT: SNTRUS3A 
  
 (b) the parties shall enter into a License Agreement dated of even date herewith (“License Agreement”); and 
  
 (c) Constar shall deliver to Continental a document executed by Rexam AB consenting to the settlement of the Action in the form attached
hereto as Exhibit 1. 
  
 2. Upon the execution of this Agreement:

  
 (a) The parties hereby release, remise, and forever
discharge one another, their predecessors, successors, parents, subsidiaries, officers, directors, agents, employees, assigns, and attorneys, from any and all claims, demands, liabilities, causes of action, damages, legal fees, costs, expenses, and
claims for compensation of whatever nature or description, arising out of or relating to the Action, and/or which have been or could have been asserted in the Action, including but not limited to any allegation that any multi-layer article including
MXD6 and cobalt neodecanoate infringes any of the Licensed Patents as that term is defined in the License Agreement. This release shall not preclude any action for breach of this Settlement Agreement or any action under the License Agreement, nor
shall any such action be considered to have rendered the release contained in this paragraph unenforceable for any reason, including for purposes of paragraph 12. 
  

 - 3 - 

 (b) Constar and ACI Operations Pty Ltd, an Australia company, and Owens-Illinois Plastics KFT (f/k/a
Continental PET Technologies Magyarorszag KFT), a Hungary company, hereby release, remise, and forever discharge one another, their predecessors, successors, parents, subsidiaries, officers, directors, agents, employees, assigns, and attorneys, from
any and all claims, demands, liabilities, causes of action, damages, legal fees, costs, expenses, and claims for compensation of whatever nature or description, arising out of or relating to the Action, and/or which have been or could have been
asserted in the Action, including but not limited to any allegation that any multi-layer article including MXD6 and cobalt neodecanoate infringes any of the Licensed Patents as that term is defined in the License Agreement. This release shall not
preclude any action for breach of this Settlement Agreement or any action under the License Agreement, nor shall any such action be considered to have rendered the release contained in this paragraph unenforceable for any reason, including for
purposes of paragraph 12. Owens-Illinois hereby represents and warrants that ACI Operations Pty LTd and Owens-Illinois Plastics KFT are indirect, wholly-owned subsidiaries of Owens-Illinois and that Owens-Illinois has authority to bind ACI
Operations Pty LTd and Owens-Illinois Plastics KFT to this Agreement. 
  
 3. The parties agree that they will execute and file, within five business days of the execution of this Settlement Agreement, any and all necessary documents to discontinue the prosecution of the Action, including all counterclaims, with
prejudice, and that each party shall bear its own costs and fees incurred in connection with the Action. 
  

 - 4 - 

 4. Continental agrees that it will not directly or indirectly contest the validity or enforceability of
the patents licensed pursuant to the License Agreement, provided, however, that if Continental is accused of infringing any of the patents licensed pursuant to the License Agreement Continental shall have the right to contest the validity,
enforceability, and alleged infringement of all such patents. 
  
 5. Any dispute arising between or among the parties to this Settlement Agreement in connection with this Settlement Agreement shall be resolved by binding arbitration to be conducted in New York, N. Y. pursuant to the commercial arbitration
rules of the American Arbitration Association. The parties shall endeavor to concur in the appointment of a single neutral arbitrator to arbitrate the dispute. In the event the parties cannot agree upon a single neutral arbitrator after reasonable
efforts, the dispute shall be referred to three arbitrators, one to be appointed by Constar, one to be appointed by Continental, and the third to be nominated by the two arbitrators so selected by the parties, or if they cannot agree upon a third,
by the American Arbitration Association. In the event that either party, within one month of any notification made to it of a demand for arbitration by the other party in accordance with this paragraph, shall not have appointed its arbitrator, such
arbitrator shall be nominated by the American Arbitration Association. The decision of any two of the three arbitrators shall be binding on all parties to the arbitration and any successors thereto. 
  
 6. This Settlement Agreement shall be construed and the legal relations
between the parties determined in accordance with the laws of the State of Delaware, excluding any choice of law rules which may direct the application of the laws of any other jurisdiction. 
  

 - 5 - 

 7. Continental shall not directly or indirectly sell or transfer any part of its business pertaining to
the manufacture and sale of Licensed Products as defined in the License Agreement without obtaining the agreement of the transferee to be bound by the obligations set forth in this Settlement Agreement (other than those set forth in paragraph 1).
Constar shall be a third party beneficiary of such agreement. 
  
 8. All notices required or permitted to be given under this Agreement shall be in writing and shall be sent by facsimile, by certified mail, or by overnight courier addressed as set forth below or to such other person or address as may be
notified in accordance with this paragraph. Any such notice shall operate and be deemed to have been served (i) if by facsimile, upon dispatch, with a facsimile confirmation of receipt; (ii) if by certified mail, three business days after dispatch;
(iii) if by overnight courier, on the following business day. 
  

 - 6 - 

 For Constar: 
  
 David J. Waksman 
 Vice President, General Counsel, 
 and Secretary 
 Constar International Inc. 
 One Crown Way 
 Philadelphia, PA 19154-4599 
  
 For
Continental: 
  
 Continental PET
Technologies, Inc. 
 One SeaGate 
 Toledo, Ohio 43666 
  
 ATTENTION: General Counsel 
  
 9. The making, execution, and delivery of this Settlement Agreement have been induced by no representation, statements, warranties, or agreements other
than those expressed herein. This Settlement Agreement embodies the entire understanding of the parties and there are no further or other agreements or understandings, written or oral, in effect between the parties relating to the subject matter
hereof, except for the License Agreement that is executed concurrent herewith. 
  
 10. This Settlement Agreement may be amended or modified only by a written instrument signed by authorized representatives of the respective parties hereto. 
  
 11. The failure of any party to enforce at any time any of the provisions of
this Settlement Agreement shall in no way be construed as a waiver of any such provision nor in any way affect the validity of this Settlement Agreement. 
  
 12. If for any reason any provision of this Settlement Agreement is held invalid, illegal, or unenforceable, such provision shall be deemed to be
severable from the other provisions of this Agreement, all of which shall remain in full force and effect and be binding upon the parties hereto, provided, however, that (i) if Constar’s release of any released party set forth in paragraph 2 is
in any way rendered unenforceable as 
  

 - 7 - 

 determined by arbitration as set forth in paragraph 5 and (ii) such released party is sued by Constar for any
matter purportedly settled or waived hereby, Constar shall immediately pay Owens-Illinois, Inc. the sum of twenty-five million one hundred thousand U.S. dollars ($25,100,000) plus interest calculated at the prime rate from the date of this Agreement
to the date of payment. Owens-Illinois, Inc. is a third-party beneficiary of this Settlement Agreement for purposes of this paragraph 12 and Owens-Illinois, Inc. shall have the right to enforce paragraph 12 but only by utilizing the arbitration
provisions of paragraph 5. 
  
 13. This Settlement Agreement may
be executed by the parties hereto in several counterparts, each of which shall be deemed to be an original, and all of which shall constitute together but one and the same agreement. 
  
 14. By executing this Settlement Agreement, each of the parties represents and warrants that it has all necessary power and
authority to execute and deliver this Settlement Agreement, that this Settlement Agreement has been duly executed and delivered by such Party, and that this Agreement is an enforceable obligation of such Party. 
  

 - 8 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Settlement Agreement to be duly executed in their
respective names by their duly authorized representatives as of the date and year first written above. 
  
  
  

							
	 CONSTAR INTERNATIONAL INC.
	 	 CONTINENTAL PET TECHNOLOGIES, INC.

				
	By:	 	 /s/ David Waksman

	 	By:	 	 /s/ James W. Baehren

	Name:	 	David Waksman	 	Name:	 	James W. Baehren
	Title:	 	Vice President, General Counsel	 	Title:	 	Agent and Attorney in Fact
	 	 	and Secretary	 	 	 	 

  
 Owens-Illinois, Inc. consents to
Paragraphs 1(a), 2(b), and 12 above. 
  
 OWENS-ILLINOIS, INC. 
  

			
	By:	 	 /s/ James W. Baehren

	Name:	 	James W. Baehren
	Title:	 	Senior Vice President

  

 - 9 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]